Status:

COMPLETED

Plasma Adsorption in Patients With Confirmed COVID-19

Lead Sponsor:

Marker Therapeutics AG

Collaborating Sponsors:

Terumo BCT

Conditions:

Respiratory Failure

ARDS

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

To characterize the ability of the D2000 Cartridge in combination with the Optia SPD Protocol to reduce the morbidity and mortality associated with SARS-CoV-2 infection in patients admitted to the ICU...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years old
  • Admitted to ICU
  • Diagnosis of SARS-CoV-2 with any one of the following conditions:
  • Early acute lung injury (ALI)/early acute respiratory distress syndrome (ARDS); or
  • Severe disease, defined as:
  • dyspnea,
  • respiratory frequency ≥ 30/min
  • blood oxygen saturation ≤ 93%
  • partial pressure of arterial oxygen to fraction of inspired oxygen ratio \< 300, and/or
  • lung infiltrates \> 50% within 24 to 48 hours; or
  • Life-threatening disease, defined as:
  • respiratory failure,
  • septic shock, and/or
  • multiple organ dysfunction or failure.
  • Patient fact sheet is provided to the subject.
  • Subject or legal representative is able and willing to give informed consent. If authorized by the IRB, emergent plasma adsorption with the D2000 cartridge may be initiated prior to consent.

Exclusion

  • Treatment limitation or a do not attempt to resuscitate in place
  • Pregnancy
  • Significant or uncontrolled bleeding
  • In the opinion of the investigator, any other condition that precludes plasma adsorption with the D2000

Key Trial Info

Start Date :

May 20 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2022

Estimated Enrollment :

107 Patients enrolled

Trial Details

Trial ID

NCT04358003

Start Date

May 20 2020

End Date

April 1 2022

Last Update

April 11 2022

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

University of Arkansas for Medical Sciences (UAMS)

Little Rock, Arkansas, United States, 72205

2

UNM Health Science Center

Albuquerque, New Mexico, United States, 87131

3

Providence Portland Medical Center

Portland, Oregon, United States, 97213

4

Reading Hospital

West Reading, Pennsylvania, United States, 19611